May 15, 2017 — A growing number of breast cancer survivors have been re-diagnosed with another type of cancer as a result of the breast implants that were used in reconstructive surgery.
Hundreds of women in the United States have been diagnosed with Anaplastic Large Cell Lymphoma (ALCL), a rare immune system cancer that is associated with breast implants.
One woman was diagnosed with breast cancer at the age of 33, underwent a double mastectomy, and received implants in both breasts in 2008.
Five years later, her right breast tripled in size as a result of fluid accumulating around the implant. Her doctor replaced the implant and tested some of the fluid. It was positive for CD30, a sign of lymphoma.
She was diagnosed with ALCL in 2013, two years after the FDA first warned about breast implant lymphoma. By March 2017, nine deaths and 359 cases of implant-associated ALCL were reported to the FDA. Dozens more cases have been reported worldwide.
The symptoms of ALCL include painful breast swelling, fluid buildup, and sometime lumps in the armpit or around the breast implant. The diagnosis requires removing some of the fluid and testing it for CD30.
The good news is that surgery to remove the implant and the scar-tissue capsule can cure 85% of women with ALCL. However, delayed diagnosis increases the risk of life-threatening complications.
Do I have a Breast Implant Lawsuit?
The Schmidt Firm, PLLC is currently accepting breast implant induced injury cases in all 50 states. If you or somebody you know has been diagnosed with lymphoma, you should contact our lawyers immediately for a free case consultation. Please use the form below to contact our Defective Medical Device Litigation Group or call toll free 24 hours a day at (866) 920-0753.
Attention Lawyers: We consider a referral from another law firm to be one of the greatest compliments. If your firm is interested in referring us a case or for us to send you a list of previous award judgments and/or average referral fees, please visit the Lawyer Referral section of our website.